| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q1 2020 | ||||||||
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CUREVAC N V | 12 | Q3 2023 | 58.0% |
| VIR BIOTECHNOLOGY INC | 12 | Q3 2023 | 32.0% |
| BIONTECH SE | 12 | Q3 2023 | 35.8% |
| ATRECA INC | 12 | Q3 2023 | 5.3% |
| AMYRIS INC | 12 | Q3 2023 | 1.2% |
| IMMUNCORE HLDGS PLC | 11 | Q3 2023 | 35.7% |
| BUTTERFLY NETWORK INC | 11 | Q3 2023 | 3.8% |
| LUMIRADX LTD | 8 | Q3 2023 | 18.0% |
| EXSCIENTIA | 8 | Q3 2023 | 13.3% |
| ZYMERGEN INC | 6 | Q3 2022 | 0.3% |
View Bill & Melinda Gates Foundation's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| LumiraDx Ltd | August 03, 2022 | 19,859,773 | 15.8% |
| Atreca, Inc. | February 16, 2021 | 1,396,644 | 4.7% |
| Liquidia Technologies Inc | February 12, 2020 | 119,678 | 0.5% |
| X4 Pharmaceuticals, Inc | March 15, 2019 | 120,363 | 1.8% |
| Arsanis, Inc. | February 13, 2018 | 722,179 | 5.1% |
View Bill & Melinda Gates Foundation's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
| SC 13D | 2022-08-03 |
| SC 13G | 2022-07-15 |
| 13F-HR | 2022-05-13 |
View Bill & Melinda Gates Foundation's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.